Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 91
   

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015’, provides an overview of the Acute Respiratory Distress Syndrome’s therapeutic pipeline.


This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.


Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Respiratory Distress Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13
Acute Respiratory Distress Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acute Respiratory Distress Syndrome - Products under Development by Companies 17
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Athersys, Inc. 20
BioMarck Pharmaceuticals, Ltd. 21
Faron Pharmaceuticals Oy 22
FirstString Research, Inc. 23
GlaxoSmithKline Plc 24
Histocell S.L. 25
Myelo Therapeutics GmbH 26
Phylogica Limited 27
Serendex Pharmaceuticals A/S 28
Silence Therapeutics Plc 29
Therabron Therapeutics, Inc. 30
Acute Respiratory Distress Syndrome - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
ALT-836 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BIO-10901 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CG-367 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Cyndacel-M - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GSK-2586881 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GSK-2862277 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
interferon beta-1a - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
molgramostim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MultiStem - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Myelo-001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PYC-35 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PYC-36 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PYC-38 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PYC-98 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
S-1229 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SAN-101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Acute Respiratory Distress Syndrome - Recent Pipeline Updates 71
Acute Respiratory Distress Syndrome - Dormant Projects 81
Acute Respiratory Distress Syndrome - Discontinued Products 83
Acute Respiratory Distress Syndrome - Product Development Milestones 84
Featured News & Press Releases 84
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 84
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases 84
Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition 85
Dec 02, 2014: Traumakine development in Japan 86
Jan 02, 2014: Promising new treatment for life threatening acute respiratory distress syndrome 86
Dec 20, 2013: Faron receives scientific advice from the EMA on the FP-1201-lyo clinical development 87
Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program 87
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 American Thoracic Society Meeting 88
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 88
May 23, 2011: Altor BioScience Receives D3m SBIR Phase II Competing Renewal Grant From NHLBI 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2015 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2015 19
Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2015 20
Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals, Ltd., H2 2015 21
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2015 22
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2015 23
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2015 24
Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H2 2015 25
Acute Respiratory Distress Syndrome - Pipeline by Myelo Therapeutics GmbH, H2 2015 26
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2015 27
Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H2 2015 28
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2015 29
Acute Respiratory Distress Syndrome - Pipeline by Therabron Therapeutics, Inc., H2 2015 30
Assessment by Monotherapy Products, H2 2015 31
Number of Products by Stage and Target, H2 2015 33
Number of Products by Stage and Mechanism of Action, H2 2015 35
Number of Products by Stage and Route of Administration, H2 2015 37
Number of Products by Stage and Molecule Type, H2 2015 39
Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 71
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2015 81
Acute Respiratory Distress Syndrome - Dormant Projects (Contd...1), H2 2015 82
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2015 83

List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2015 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Early Stage Products, H2 2015 16
Assessment by Monotherapy Products, H2 2015 31
Number of Products by Top 10 Targets, H2 2015 32
Number of Products by Stage and Top 10 Targets, H2 2015 32
Number of Products by Top 10 Mechanism of Actions, H2 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 34
Number of Products by Routes of Administration, H2 2015 36
Number of Products by Stage and Routes of Administration, H2 2015 36
Number of Products by Molecule Types, H2 2015 38
Number of Products by Stage and Molecule Types, H2 2015 38

Published By: Global Markets Direct
Product Code: Global Markets Direct13401


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: